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ABSTRAK 
 
Tajuk:   Kajian tentang kelainan analisa denyutan jantung janin membandingkan ubat tahan 
sakit epidural ropivacaine 0.2% ditambah fentanyl 2ug/ml dengan bupivacaine 0.1% ditambah 
fentanyl 2ug/ml semasa bersalin. 
 
Latar Belakang dan Objektif:  Ubat tahan sakit epidural melegakan rasa sakit bersalin secara 
efektif dan ramai ibu bersalin memilih teknik tersebut. Keselamatan janin dalam kandungan 
semasa bersalin penting dan kebanyakan pembiusan separuh badan sewaktu bersalin 
mempengaruhi denyutan jantung janin. Pelbagai kajian telah dilakukan untuk membandingkan 
kepekatan ubat bius setempat serta  teknik pembiusan separuh yang berlainan untuk menganalisa 
kesan terhadap kadar denyutan jantung janin dan kesan terhadap cara melahirkan anak, kesan 
terhadap kestabilan ibu serta bayi. Jadi, kajian ini bertujuan untuk menganalisa kadar denyutan 
jantung semasa menggunakan dua kepekatan berlainan bagi ubat tahan sakit epidural dan kesan 
terhadap cara melahirkan bayi, kestabilan ibu serta keadaan bayi semasa lahir. 
 
Keputusan:   Berdasarkan cara melahirkan anak, ibu yang bersalin secara spontan bagi 
kumpulan yang menggunakan ropivacain adalah seramai 48 orang (71.6%) dengan bupivacaine 
pula adalah seramai 49 orang (83.1%). Bagi kelahiran melalui Caesarean pula kumpulan 
ropivacain adalah seramai 15 orang (22.4%) dan bagi bupivacaine pula ialah seramai 10 orang 
(16.9%). Perbandingan di antara kedua-dua kumpulan ubat bius setempat menunjukkan tiada 
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perbezaan yang bermakna dalam cara melahirkan anak. Seramai 115 ibu bersalin menunjukkan 
kadar denyutan jantung bayi yang normal di mana 96 orang (83.5%) dari mereka melahirkan 
secara spontan, 2 orang (1.7%) melahirkan secara instrumental dan selebihnya iaitu 17 orang 
(14.8%) menjalani pembedahan Caesarean. Dalam pada itu 11 ibu bersalin menunjukkan kadar 
denyutan jantung janin yang tidak normal, di mana 1 orang (9.1%) melahirkan secara spontan, 2 
orang (18.2%) melahirkan secara instrumental dan seramai 8 orang (72.7%) secara pembedahan 
Caesarean. Ibu bersalin yang menunjukkan CTG yang tidak normal mempunyai peratusan yang 
lebih tinggi untuk bersalin secara pembedahan Caesarean. Seramai 27  ibu yang bersalin secara 
pembedahan Caesarean di mana seramai 18 orang menunjukkan CTG yang normal, 4 orang 
(22.2%) mengalami kelahiran tersekat, 2 orang (11.1%) mengalami kelemasan janin dan 
selebihnya 12 orang (66.7%) mengalami proses kelahiran yang lambat. Ibu yang menunjukkan 
CTG yang tidak normal, seramai seorang (11.1%) mengalami kelahiran tersekat manakala 8 
orang (88.9%) mengalami kelemasan janin dengan nilai p=<0.001 yang bermakna. Tiada 
perbezaan bermakna dilihat dari segi kestabilan ibu serta bayi semasa lahir. 
 
Kesimpulan: Berdasarkan kajian ini, ubat tahan sakit secara epidural sewaktu bersalin 
menggunakan ropivacain 0.2% dan bupivacain 0.1% dengan fentanyl 2ug/ml di dapati tidak 
memberikan perubahan dalam denyutan jantung janin. Terdapat peningkatan kadar pembedahan 
Caesarean disebab oleh CTG yang tidak normal dari kumpulan ropivacain diakibatkan 
kelemasan janin. Tiada perubahan dalam kestabilan ibu dan bayi yang dilahirkan. 
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ABSTRACT 
 
Title:  A study on analysis of foetal heart rate abnormalities comparing epidural analgesia 
ropivacaine 0.2% with fentanyl 2ug/ml to bupivacaine 0.1% with fentanyl 2ug/ml during labour. 
 
Background and Objectives: Epidural analgesia effectively relieves labour pain and is widely 
chosen by parturients. Foetal well being is also important during labour as various neuraxial 
analgesia in labour is known to influence FHR tracings. Various studies focused on equipotent 
doses of local anesthetics and compared different techniques of labour analgesia in assessing 
foetal heart rate changes and its outcome on mode of delivery, effects on maternal 
haemodynamics and the neonatal outcome based on APGAR score. Therefore, this study was 
intended to analyze foetal heart rate changes using two different concentrations of epidural 
analgesia with opioids and its effect on the mode of delivery, maternal haemodynamics and 
neonatal outcome. 
 
Methodology:   A total of 126 patients were recruited in this prospective randomized cross 
sectional study. Maternal haemodynamics and foetal heart rate monitoring is documented 15 
minutes before epidural administration and 15 minutes after epidural administration and 
subsequently every 30 minutes till four hours. CTG interpretation is documented. The observed 
outcome in this study were foetal heart rate abnormalities post epidural, maternal 
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haemodynamics before and after epidural analgesia in labour, mode of delivery and the neonatal 
APGAR score. 
Result:   Based on the mode of delivery between both the groups of epidural analgesia 
ropivacaine and bupivacaine, there were 48 (71.6%) in the ropivacaine group and 49 (83.1%) in 
the bupivacaine group who delivered spontaneously. 4 (6%)  only delivered via instrumental in 
the ropivacaine group. Via caesarean section 15 (22.4%) in the ropivacaine group and 10 
(16.9%) in the bupivacaine group. There were no significant changes in the mode of delivery 
between both the groups. 115 parturients had normal FHR, 96(83.5%) delivered spontaneously, 2 
(1.7%) had instrumental delivery, 17 (14.8%) delivered via caesarean section. Whereas 11 
patients had abnormal FHR, 1 (9.1%) delivered spontaneously, 2 (18.2%) via instrumental 
delivery and 8 (72.7%) via caesarean delivery. A higher percentage in caesarean delivery with 
abnormal CTG with a significant p value <0.001. Parturients for caesarean section were 27, 18 
had normal CTG out of which 4 (22.2%) for secondary arrest, 2 (11.1%) for acute foetal distress, 
12 (66.7%) for poor progress. 9 parturients had abnormal CTG, out of which 1 (11.1%) for 
secondary arrest, 8 (88.9%) for acute foetal distress with a significant p value=<0.001.There 
were no significant difference seen in maternal outcome and neonatal outcome. 
 
Conclusion:   This study revealed that with epidural analgesia in labour using ropivacaine 0.2% 
and bupivacaine 0.1% with fentanyl 2ug/ml, there were no foetal heart rate changes. There were 
increased risk for caesarean delivery with abnormal CTG in the ropivacaine group due to acute 
foetal distress. There were no changes in the maternal and neonatal outcome. 
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CHAPTER 1 
 
INTRODUCTION 
 
Foetal well being is the most important aspect during labour.To determine foetal well-
being, one of the ways is by recording the foetal heart rate (FHR). Loss of beat to beat 
variability and deceleration patterns are known to be associated with foetal distress. 
Gynaecological factors, maternal and foetal factors, but also anaesthesiological factors 
can influence these FHR tracings. Decelerations and foetal bradycardia have been 
described after all types of effective labour analgesia such as (epidural,spinal,and 
combined spinal epidural(CSE) and intravenous opioids.(Nicole Maria Anna Adela 
Engel, 2011). 
 
Epidural analgesia effectively relieves labour pain and is now widely chosen by 
parturients. In the US the use of neuraxial analgesia for labour increased to 77% in 
2001 from 21% in 1981 and a little over 33% of parturients chose neuraxial analgesia 
for childbirth in UK from 2008-2009.(Cambic and Wong)2010. The additional use of 
opioids increases the effect of local anesthetic allowing the use of minimal 
concentration of local anesthetic, reducing the side effects such as hypotension and 
motor block. The minimum effective doses are used to avoid interference with the 
progression of labour and permit ambulation, however transient foetal heart rate(FHR) 
changes may occasionally follow with the use of any technique.(Capogna, 2001) 
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The beneficial effects of epidural analgesia may be offset by the detrimental effects 
such as prolonged labour, higher incidence of instrumental delivery and Caesarean 
section, maternal factor such as (hypotension,epidural haematoma and epidural 
abscess) and also towards the neonatal outcome. Although numerous studies have been 
done on the effects of epidural analgesia the results are contradictory. 
 
(Cambic and Wong)2010 conducted a study and the evidence of neuraxial analgesia on 
labour outcome shows that neuraxial analgesia does not increase the risk of caesarean 
delivery .Conflicting evidence but overall it suggests increased rate of instrumental 
vaginal delivery in women receiving neuraxial labour analgesia.This was mainly 
affected by multiple factors, such as the degree of analgesia during second stage of 
labour, local anaesthetic concentration, method of epidural analgesia maintenance, 
technique and obstetric factors. There were no difference in the duration of first stage 
of labour and effective neuraxial analgesia increases the duration of second stage of 
labour. 
 
A systemic review was done by (Leighton and Halpern, 2002) and their findings 
showed that parturients preferred epidural analgesia compared to parenteral opioids and 
they were more comfortable and satisfied,The length of first stage and second stage of 
labour were prolonged and the total incidence of instrumental delivery was higher in 
the epidural group. Neonatal outcome between the two groups showed no difference or 
more so favoured epidural analgesia. There were no significant trend toward an 
increase in the total number of caesarean delivery compared to the previous systemic 
review.(Halpern et al., 1998). 
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In relation to dose related epidural analgesia there were numerous studies comparing 
bupivacaine and ropivacaine for labour analgesia. A randomized double blinded study 
by(Lee et al., 2004) comparing epidural infusions of  ropivacaine 0.1% with 2ug/ml of 
fentanyl with bupivacaine 0.1% with 2ug/ml Fentanyl focused on the obstetric outcome 
where the mode of delivery was similar between the two groups. Parturients who 
delivered vaginally, the duration of the first stage of labour was shorter in the 
ropivacaine group compared with the bupivacaine group. Incidence of maternal and 
neonatal outcome were similar between both the groups. 
 
Another study was conducted by (Halpern and Walsh, 2003) which was a meta analysis 
also concluded that both ropivacaine and bupivacaine provided excellent  labour 
analgesia and there is no significant difference between the two drugs with regards to 
neonatal, spontaneous vaginal delivery or any other obstetrical oucome. A randomized 
double blinded study(Fischer et al., 2000) compared the administration of 0.1% 
ropivacaine and 0.5 ug/ml sufentanil with bupivacaine 0.1% and 0.5ug/ml sufentanil 
via a PCEA device. Outcome of this study  produced effective pain relief in both the 
groups but maternal satisfaction was greater with the bupivacaine group. Ropivacaine 
drug was used more than bupivacaine during the second stage of labour, concluding 
that ropivacaine was less potent compared to bupivacaine and also due to the reduction 
in motor impairment. 
 
Many studies were done on neuraxial analgesia in labour with different techniques, 
comparisons of equipotent concentrations of local anesthesia, comparisons with 
parenteral analgesia in labour with and without opioids and all these studies were 
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focused on the outcomes of maternal, neonatal and mode of delivery. There a few 
studies  which has focused on the foetal wellbeing post neuraxial analgesia. A study on 
the incidence and clinical significance of foetal heart rate changes using intrathecal 
sufentanil or epidural bupivacaine for labour analgesia(Nielsen et al., 1996),there were 
no significant difference in foetal heart rate between these two groups and also to the 
neonatal outcome. 
 
A review on the effect of epidural analgesia on the foetal heart rate(Capogna, 2001) 
concluded that epidural or spinal analgesia in the absence of maternal hypotension or 
uterine hypotonus causes minimal changes in FHR. Even if there were it is transient 
and should not produce maternal or foetal morbidity. A recent French study (Korb et 
al.) analyzed foetal heart rate abnormalities occurring within one hour after laying of 
epidural analgesia using 0.1% levobupivacaine and sufentanil 0.2ug/ml. The results 
showed an increase in obstetric intervention in the abnormal foetal heart rate group and 
an absence of impact in the neonate state. 
 
The importance of this study is to characterize abnormalities in the foetal heart rate by 
using two different concentration of epidural analgesia  and its effect on the mode of 
delivery and neonatal outcome. The aim of this study is to characterize the 
abnormalities in FHR with ropivacaine 0.2%+ 2ug fentanyl and bupivacaine 0.1% + 
2ug fentanyl, and its outcome on the mode of delivery and neonatal status. It attempts 
to address the potencies of different concentrations of the local anesthetic towards 
foetal heart rate abnormality during epidural analgesia in labour. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1   Foetal Heart Rate  
The foetal brain modulates the foetal heart rate through an interplay of sympathetic and 
parasympathetic forces. Foetal heart rate(FHR) monitoring can be used to determine if 
a foetus is well oxygenated. Despite the frequency of its use, limitations of EFM 
(electronic foetal monitoring) include poor interobserver and intraobserver reliability, 
uncertain efficacy and a high false positive rate. Foetal heart rate monitoring may be 
performed externally or internally. Most external monitors use a Doppler device with 
computerized logic to interpret and count the Doppler signals. Internal FHR monitoring 
is accomplished with a foetal electrode, which is a spiral wire placed directly on the 
foetal scalp or other presenting part.(Obstetricians and Gynecologists, 2009) 
Figure 2.1 Cardiotochograph Machine 
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Foetal heart sounds were said to be first detected by Marsac in the 1600’s. Killian 
proposed that foetal heart rate could be used to determine foetal well being in the 
1600’s. This thought went unnoticed until 1818 when Mayor and Kergaradec described 
the method of  auscultating foetal heart sounds by placing the ear next to the maternal 
abdomen. Kergaradec also suggested that foetal heart sounds could be used to 
determine foetal life and multiple pregnancy and if it would be possible  to assess foetal 
abnormalities from variations in the foetal heart rate. Evory Kennedy, an English 
physician, published guidelines for foetal distress and recommended auscultation of the 
foetal heart rate as a tool of intrapartum monitoring in 1833. By 1893, Von Winkel 
developed a criteria for foetal distress that remained unchanged until the arrival of 
electronic fetal monitoring.(Alfirevic et al., 2006)  
 
Since then, many methods of listening to the foetal heart have been developed and 
introduced into maternity care, with the goal of improving outcomes for neonates and 
easing the heartache for mothers and families when a baby dies or suffers long-term 
disability. For now, monitoring the foetal heart during labour, by one method or 
another, has become a routine part of care during labour, although access to such care 
are different across the world.(Alfirevic et al., 2006) 
 
2.2 Foetal Heart Rate Monitoring 
 
Methods of monitoring the foetal heart rate 
The foetal heart rate can be monitored either intermittently (at regular intervals during 
labour) or continuously (recording the foetal heart rate throughout labour, stopping 
only briefly, e.g. for visits to the toilet) as follows. 
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(1) Fetal stethoscope (Pinard) and hand-held Doppler 
Intermittent monitoring can be undertaken either by listening to the foetal heart rate 
using a foetal stethoscope (Pinard) or a handheld Doppler ultrasound device and by 
palpating the mother’s uterine contractions by hand. This is known as ’intermittent 
auscultation’. 
 
 
Figure 2.2   Pinard’s Stethoscope 
 
 
 
Figure 2.3   Hand-held Doppler device 
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(2) Cardiotocograph (CTG) 
 
Cardiotocograph electronically records the foetal heart rate and the mother’s uterine 
contractions on a paper trace. External CTG: This is obtained by using a Doppler 
ultrasound transducer to monitor the foetal heart rate and a pressure transducer to 
monitor uterine contractions, both are connected to a recording machine. Internal 
CTG: Monitors the foetal heart rate with the CTG machine by attaching an electrode 
directly to the baby’s presenting part usually its head. It is a form of continuous 
monitoring  and requires a ruptured amniotic sac (either spontaneously or artificially) 
and a scalp electrode (clip) attached to the foetal head.(Alfirevic et al., 2006). 
 
CTG monitoring and a systematic approach to CTG analysis may enable anaesthetists 
to better understand why obstetricians make specific clinical decisions. This 
understanding may aid communication and timely delivery especially when the foetus 
is considered at high risk.(ATOTW, 2013).Parturients receiving regional analgesia in 
labour, requires continuous electronic fetal monitoring for at least 30 minutes during 
establishment of regional analgesia and after administration of a further bolus of local 
anaesthetic agent. In most UK centres, continuous CTG monitoring is performed after 
the insertion of a labour epidural.(ATOTW,2013) 
 
2.3 Baseline Fetal Heart Rate 
 
The normal baseline foetal heart rate is defined as 110 – 160 bpm. Foetal bradycardia is 
a baseline rate of <110 bpm. Foetal tachycardia is a baseline rate of >160 bpm. Many 
foetal baseline bradycardias have no identifiable cause but may occur as a result of: 
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Cord compression and acute foetal hypoxia, post-maturity (> 40 weeks gestation) and 
congenital heart abnormality. Foetal tachycardia is associated with, excessive foetal 
movement or uterine stimulation, maternal stress or anxiety, maternal pyrexia, foetal 
infection, chronic hypoxia and prematurity (<32 weeks gestation)(ATOTW, 2013)  
 
 
Figure 2.4  Normal CTG with the FHR upper and the tocogram below 
 
 
 
2.4  Foetal Heart Rate Variability 
 
Variability refers to the normal beat to beat changes in FHR. Normal variability is 
between 5-15 bpm. Variability is measured by analyzing a one-minute portion of the 
CTG trace and assessing the difference between the highest and lowest rates during that 
period. Variability can be defined as: Normal 5-15 bpm , increased > 15 bpm , 
decreased <5 bpm, absent < 2 bpm. Foetal hypoxia causes absent, increased or 
decreased variability. Other causes of decreased variability include: normal foetal 
sleep-wake pattern, prematurity and following maternal administration of certain drugs 
including opioids. ATOTW,2013 
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2.5  Acceleration 
 
Accelerations are periodic, temporary increases in FHR, characterized as an increase in 
FHR >15 bpm for more than 15 seconds. When accelerations are present, the CTG is  
reactive. Accelerations are associated with foetal activity and are considered as a  sign 
that the foetus is healthy. 
 
Figure 2.5   Foetal Heart Rate Acceleration 
 
 
2.6  Deceleration 
 
Decelerations are periodic, temporary decreases in FHR, and it’s related to uterine 
contractions. They are categorized into four main types by their shape and timing in 
relation to uterine contractions. Uterine contractions must be monitored adequately in 
order for a deceleration to be correctly classified. Decelerations may be, early, late, 
variable and  prolonged. 
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2.6.1  Early Deceleration 
 
Early decelerations occur with each contraction and are uniform in shape. Early FHR 
decelerations appear as if reflecting the uterine contraction trace. The beginning of the 
deceleration occurs at the onset of the contraction and the baseline FHR recovers by the 
end of the contraction. The FHR usually does not fall by more than 40 bpm during an 
early deceleration. Compression of the foetal head during a contraction is the cause of 
early deceleration. These can be relieved by changing maternal posture and are a 
normal finding in the second stage of labour. They are not associated with a poor foetal 
outcome. 
 
Figure 2.6   Foetal Heart Rate early deceleration 
 
 
2.6.2  Late Deceleration  
 
Late decelerations are uniform in shape on the CTG, but unlike early decelerations start 
after the peak of the uterine contraction. A deceleration in which the lowest point 
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occurs more than 15 seconds after the peak of the uterine contraction is defined as a late 
deceleration. They are usually associated with a reduction in the variability of the 
baseline FHR. Late decelerations are associated with decreased uterine blood flow and 
can occur as a result of: hypoxia, placental abruption, cord compression/prolapsed, 
increased uterine activity and maternal hypotension/hypovolaemia.ATOTW,2013 
 
 
Figure 2.7   Foetal heart rate late deceleration 
 
 
2.6.3  Variable Deceleration 
 
Variable decelerations describe FHR decelerations that are both variable in timing and 
size. They may be accompanied by increased variability of the FHR. They are caused 
by compression of the umbilical cord and may reflect foetal hypoxia. 
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Figure 2.8   Foetal heart rate variable deceleration 
 
 
2.6.4 Prolonged deceleration/bradycardia 
 
A deceleration with a reduction in FHR of greater than 30 bpm that lasts for at least 2 
minutes is termed a prolonged deceleration They are caused by a decrease in oxygen 
transfer to the foetus so can arise as a consequence of a wide variety of disorders 
including: maternal hypotension, umbilical cord compression and uterine 
hypertonia.(ATOTW,2013). 
 
Figure 2.9   Foetal heart rate prolonged deceleration/bradycardia 
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2.7  Characteristics of CTG 
A combination of several abnormalities increases the likelihood of foetal distress. 
Suspicious or abnormal features include: baseline FHR outside normal range of 110 – 
160 bpm, baseline variability <5 bpm, reduced or absent accelerations and presence of 
decelerations. 
 
2.8  Medications that effect the foetal heart rate 
 
Foetal heart rate patterns can be influenced by the medications administered in the 
intrapartum period. These changes are transient, although they sometimes lead to 
obstetric interventions. Local anesthetic agents such as lidocaine and bupivacaine for 
epidural analgesia can lead to sympathetic blockade, maternal hypotension, transient 
uteroplacental insufficiency, and alterations in the FHR. Parenteral opioids also may 
affect the FHR.(Obstetricians and Gynecologists, 2009). A study comparing epidural 
analgesia with 0.25% of bupivacaine and intravenous meperidine reported that the 
variability was decreased, and FHR accelerations were significantly less common with 
parenteral analgesia compared with regional analgesia.(Hill et al., 2003).A systematic 
review noted that there were no difference between those who did and those who did 
not receive epidural analgesia during labour in the rate of caesarean delivery for non 
reassuring FHR but this was associated with maternal hypotension or uterine 
hyperstimulation.(Lieberman and O'Donoghue, 2002). 
 
 
Regarding combine spinal epidural analgesia in labour, there was a study conducted 
with 10ug of intrathecal  sufentanyl with epidural bupivacaine and fentanyl or 
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intravenous meperidine(opioid). The results showed a significantly higher rate of 
bradycardia and caesarean delivery for abnormal FHR in the CSE group however the 
neonatal outcome were  not significantly different between the two groups.(Gambling 
et al., 1998).Another study comparing combine spinal analgesia with epidural 
analgesia, noted that FHR abnormalities were more common in the combine spinal 
epidural group.(Trial et al.) 
 
There are also other drugs which can affect foetal heart rate such as butorphanol which 
causes a transient sinusoidal FHR pattern with a slight increased mean heart rate 
compared with meperidine.(HATJIS and MEIS, 1986). Cocaine causes decreased long 
term variability in the foetal heart rate.(Forman and Gandhi, 1991). Corticosteroids 
causes decrease in FHR variability and this happens with beta-methasone and not with 
dexamethasone. It causes abolishment of diurnal foetal rhythm and this effect usually 
occurs more than 29 weeks of gestation.(Rotmensch et al., 1999). Magnesium sulphate 
causes a significant decrease in short term variability and it inhibits the increase in 
accelerations with advancing gestational age.(Hallak et al., 1999). Terbutaline causes 
an increase in baseline FHR and incidence of foetal tachycardia.(Roth et al., 1990). 
 
There are other factors which causes changes in foetal heart rate such as maternal 
position as a cause of severe FHR changes after epidural bupivacaine labour analgesia. 
This is due to occult aortocaval compression.(Preston et al., 1993). Maternal 
hypotension too has been associated to foetal bradycardia after epidural or spinal 
analgesia.Uterine hypertonus has been associated with foetal bradycardia after 
induction of labour analgesia such as CSE compared to epidural.(Landau et al., 2009) 
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2.9   Labour Pain 
 
For most women labour causes severe pain, it is similar to that caused by complex 
regional pain syndrome. The American College of Obstetricians and Gynecologists and 
the American Society of Anesthesiologists (ASA) stated that, “There is no other 
circumstance where it is considered acceptable for an individual to experience 
untreated severe pain, amenable to safe intervention, while under a physician’s 
care.(Obstet Gynecol,2004). Without a medical contraindication, maternal request is a 
sufficient medical indication for pain relief during labour. Although severe pain is not 
life-threatening in healthy parturient women, it can have neuropsychological 
consequences. Postnatal depression may be more common when analgesia is not 
used.(Hiltunen et al., 2004).And pain during labour has been correlated with the 
development of post-traumatic stress disorder.(Soet et al., 2003). 
 
2.9.1   Physiology of pain in labour 
 
Labour pain is caused by uterine contractions and cervical dilatation and is transmitted 
through visceral afferent(sympathetic) nerves entering the spinal cord from T10 
through L1. Later in labour, perineal stretching transmits painful stimuli through the 
pudendal nerve and sacral nerves S2 through S4. The maternal stress response can lead 
to increased release of corticotropin, cortisol, norepinephrine, β-endorphins, and 
epinephrine. Epinephrine can have relaxant effects on the uterus that may prolong 
labor.(Hawkins, 2010). 
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2.9.2  Acute Pain Pathway 
 
Figure 2.10   Pain is transducted via small A delta and C afferent nociceptive 
fibres to the dorsal horn cell in the spinal cord. 
 
 
 
Clinical pain is a result of either tissue injury (inflammatory) or nerve injury 
(neuropathic). When tissue injury occurs, a large number and variety of chemical 
mediators are liberated. These include hydrogen ions, noradrenaline, bradykinin, 
histamine, potassium ions, prostaglandins, purines, cytokines, 5-hydroxytryptamine, 
leukotrienes, nerve growth factor and neuropeptides. These substances in turn stimulate 
the small A delta and C afferent pain fibres.(Woolf and Chong, 1993). The terminals of 
small A delta and C afferent fibres act as receptors for nociception from superficial 
structures (skin and subcutaneous tissue), deep structures (muscle, fascia) and 
viscera.(Figure 2.10). These afferents pass within nerve fibres to the dorsal horn of the 
spinal cord where they either terminate superficially or pass more deeply into the dorsal 
horn laminae.(Rowlands and Permezel, 1998) 
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Action potentials generated within the dorsal cell neurone may participate in local 
spinal reflexes in which anterior and anterolateral horn cells stimulate skeletal muscle 
and sympathetic outflow. The action potential is also relayed centrally via the 
spinothalamic tract (Figure 2.11), from which the impulse is modulated successively by 
the reticular formation in the brainstem (integrative function), thalamus (level of 
arousal), hypothalamus and limbic systems (attention, mood and motivation). 
Nociception is modulated at the level of the dorsal horn by descending spinal tracts, 
which receive input from higher centres and the limbic system via stimulation of 
structures in the midbrain. This phenomenon is called 'stimulation-produced analgesia'. 
The type of nociceptive input appears to determine the descending tract stimulated and 
thus the neurotransmitter response.(Rowlands and Permezel, 1998). 
 
 
Mechanical nociception activates the synthesis of β-endorphin which stimulates 
supraspinal opioid receptors and results in spinal release of enkephalins. Other 
endogenous opioids are known to be involved in the spinal modulation of nociception; 
proenkephalin is the precursor for met-enkephalin and other enkephalins which act by 
interaction with 'δ-opioid' receptors  and dynorphin derived from prodynorphin 
interacts with 'κ-opioid' receptors.(Tseng et al., 1995). Following the occupation of the 
opioid receptors on the dorsal horn neurones, the anti-nociceptive effect is produced by 
attenuation of the primary afferent nociceptive input, by inhibition of propagation of 
the action potential along the dorsal horn cell or by reducing the release of excitatory 
neurotransmitter substances from primary afferent terminals. 
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Figure 2.11 Ascending pathways 
 
Figure 2.12 Descending pathway 
 
 
 
20 
 
2.9.3  Labour pain during first stage 
 
The source of uterine nociception is not determined.During the first stage of labour, 
pain is predominantly mediated by mechanical distension of the lower uterine segment 
due to the mechanical dilatation of the cervix and the muscle contraction.The 
contraction of the uterus causes stretching and injury and thus causes the excitation  of 
nociceptive afferents. During this stage a paracervical block with Bupivacaine has been 
shown to reduce pain significantly, proving that the cervix is an important source of 
pain at this time.(Ranta et al., 1995).Strong contractions generated under isometric 
conditions in the presence of an abnormal fetal lie or slowly dilating cervix are 
frequently very painful. During labour, pain increases progressively due to the increase 
in duration and intensity of contractions. 
 
The uterus and cervix are supplied by afferents that accompany the sympathetic nerves 
in the uterine and cervical plexus, the inferior hypogastric plexus, the superior 
hypogastric  plexus and the aortic plexus.(Figure 2.5).Pain is transmitted via small 
unmyelinated slow conducting C visceral fibres.They pass through the lumbar and 
lower thoracic sympathetic chain to the posterior nerve roots of the 10th,11th and 12th 
thoracic and 1st lumbar nerves to make synaptic contact with the interneurones in the 
dorsal horn. Bradykinin,  leukotrienes ,serotonin, substance P, prostaglandins and lactic 
acid are the chemical mediators that cause the excitation of these fibres.(Rowlands and 
Permezel, 1998).Contraction pain is transmitted slowly and its poorly localized. It is 
referred to the dermatomes supplied by T10, T11,T12 and L1.During the early first 
stage its felt as a dull ache over the area supplied by T11and T12. As the labour 
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progresses, pain increases and becomes more severe and is referred to the abdomen, 
lower lumbar and upper sacrum supplied by T10 and L1. 
 
2.9.4  Labour pain during second stage 
Distension of the lower segment and cervix continues to cause pain with similar 
distribution at, the first stage.In the second stage, increasing pressure is exerted by the 
presenting part within the pelvis. Pain at this stage is usually described as sharp and 
localized to the perineum, anus and rectum but also felt in the thighs or legs.This is due 
to the traction and pressure on the parietal peritoneum, uterine ligaments, urethra, 
bladder, rectum, lumbosacral plexus, fascia and muscles of the pelvic floor. Due to the 
direct pressure of the presenting part on the lumbosacral plexus, neuropathic pain 
occurs.Pudendal nerve arising from the S2, S3 and S4 via fine myelinated rapidly 
transmitting A delta fibres is stimulated as the vagina and perineum is 
stretched.Impulses pass to the dorsal horn cell and then via the spinothalamic tract to 
the brain.(Rowlands and Permezel, 1998) 
 
Figure 2.13  Neural pathway in labour 
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Segmental and suprasegmental reflex responses from the pain of labour may effect 
respiratory, cardiovascular, gastrointestinal, urinary and neuroendocrine function.These 
responses are mediated by pain and its evidenced by the fact that they can be prevented 
or abolished by central neural blockade.(Rowlands and Permezel, 1998). 
 
2.10.1  Neuraxial analgesia in labour 
Figure 2.14. Various neuraxial analgesia in labour 
 
 
There are various methods of neuraxial analgesia in labour as shown in the above 
diagram,(Lumbar epidural, combine-spinal epidural, paravertebral block, lumbar 
sympathetic block, saddle block, paracervical block, pudendal block and sacral nerve 
roots block). The focus of the study is based on lumbar epidural analgesia in labour. 
Epidural analgesia for labor and delivery involves the injection of a local anesthetic 
agent (e.g.,lidocaine or bupivacaine) and an opioid analgesic agent (e.g., morphine or 
fentanyl) into the lumbar epidural space (Fig 2.15). The injected agent gradually 
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diffuses across the dura into the subarachnoid space, where it acts primarily on the 
spinal nerve roots and to a lesser degree on the spinal cord and paravertebral nerves. In 
spinal analgesia, which is often combined with epidural analgesia, the analgesic agent 
is injected directly into the subarachnoid space, resulting in a more rapid onset of 
effect. Successful epidural analgesia produces a segmental sympathetic and sensory 
nerve block and a decrease in endogenous catecholamines with the onset of pain 
relief.(Abboud et al., 1983).Hypotension or normalization of blood pressure to 
prelabour levels may occur with vasodilatation, which may result from sympathetic 
nerve blockade and a decrease in circulating catecholamines. Other side effects are 
FHR abnormalities and prolonged second stage of labour. 
 
Advantages of epidural analgesia in labour is its effective, with the addition of opioids 
to the reduced dose of local anesthetics causes faster onset of analgesia, due to the 
lower dose there is lesser motor blockade and allows parturients to ambulate. 
 
Figure 2.15  Epidural analgesia and combined spinal-epidural analgesia 
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2.10.2  Anatomy of the Lumbar Spine 
 
The lumbar vertebra has a larger kidney-shaped body and its vertebral foramen is larger 
than that of the thoracic vertebra. Its transverse processes are long and slender and its 
articular processes are directed (superior) posteromedially and (inferior) anterolaterally. 
Its spinous process is shorter, broader and more horizontal than those of the thoracic 
vertebrae.The articular surfaces of the bodies of adjacent vertebrae are covered by 
hyaline cartilage and united by a thick fibrocartilaginous intervertebral disc. These are 
strong cartilaginous joints designed for weight-bearing. The disc is a shock absorber, its 
centre, the nucleus pulposus, is gelatinous and surrounded by a fibrous part, the annulus 
fibrosus. Adjacent vertebrae articulate by two synovial facet joints between the paired 
articular processes.(AnesthesiaUK,2004) 
Figure 2.16 Anatomy of the lumbar vertebra 
 
 
